07 May 2019 | News
Skyhawk will use its SkySTAR™ platform to develop drug candidates directed to multiple targets for neurodegenerative diseases.
image credit- wsj.com
US based Skyhawk Therapeutics, Inc. has announced a strategic collaboration with Japan headquartered Takeda Pharmaceutical Company Limited in which Skyhawk will use its SkySTAR™technology platform to discover and pre-clinically develop innovative small molecule treatments directed to certain neurological disease targets.
The agreement grants Takeda an exclusive worldwide license to develop and commercialize compounds and products directed to multiple targets while Skyhawk receives an upfront payment and is eligible to receive future milestone payments and royalties.
As part of the agreement, Takeda will be responsible for clinical development and potential commercialization.
"Takeda is a leading global biopharmaceutical company with a strong focus in neuroscience and a history of developing transformative therapies across a range of challenging diseases," said Bill Haney, co-founder and chief executive officer of Skyhawk. "We look forward to working with their team with the goal of enhancing the treatment options we can bring to patients."